Jeffrey Veach

Assessment of Clinician Awareness of Nonadherence Using a New Structured Rating Scale

J. Lindenmayer, J. Docherty, W. Macfadden, 2010, Journal of psychiatric practice.

A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

M. Farlow, R. Anand, R. Hartman, 2000, European Neurology.

An efficacy and safety analysis of Exelon® in Alzheimer’s disease patients with concurrent vascular risk factors

R. Anand, R. Hartman, J. Messina, 2000, European journal of neurology.

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.

A. Hake, M. Farlow, R. Anand, 2001, Archives of neurology.

Long-term effects of rivastigmine in moderately severe Alzheimer's disease Does early initiation of therapy offer sustained benefits?

K. Krishnan, P. Doraiswamy, R. Anand, 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease

S. Potkin, R. Anand, R. Hartman, 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty‐two classes of medications

R. Anand, G. Grossberg, H. Stahelin, 2000, International journal of geriatric psychiatry.

Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.

Steven Potkin, Martin Farlow, S. Potkin, 2003, Archives of neurology.

Assessment of Clinician Awareness of Nonadherence Using a New Structured Rating Scale

J. Lindenmayer, J. Docherty, W. Macfadden, 2010, Journal of psychiatric practice.